Immunicum Develops a Cancer Vaccine that Almost Doubled the Patients’ Survival
News Aug 11, 2015
Immunicum reports updated survival data from the Company's phase I/II study in patients with metastatic renal cancer treated with the cancer vaccine INTUVAX. Seven of the 11 patients evaluable for efficacy are still alive. Six of the 11 patients have received add-on treatment with some type of tyrosine kinase inhibitor. Median overall survival for the entire patient group is currently at 26.5 months versus expected 15.2 months (historical data for newly diagnosed patients with metastasized renal cell cancer receiving standard treatment with tyrosine kinase inhibitor Sutent/sunitinib). For the poor prognosis group (6 patients), the median overall survival is currently at 25.5 months versus expected 9 months and for patients with intermediate risk prognosis (5 patients), the median overall survival is currently at 32 months compared to expected 26 months. The final median overall survival has not yet been reached for any of the three patient groups.
It is very encouraging that the median overall survival for INTUVAX-treated renal cancer patients continues to increase. For the high-risk group, we note a current median overall survival that is close to tripled compared to the expected median overall survival for patients receiving standard treatment with sunitinib. We have now initiated a comprehensive phase II study in the same indication where we, thanks to the open design, expect to be able to provide a first status update around the end of the year, says Immunicum’s CEO, Jamal El-Mosleh.
The purpose of the phase I/II study was to document the safety profile and immunological effects, as well as to follow the survival of patients with metastatic renal cell cancer after two INTUVAX treatments.
Combining Different Malaria Vaccines Could Reduce Cases by 91%News
Using two experimental anti-malarial vaccines, which work in different ways, can greatly reduce the number of malaria infections in animal studies. Experimental vaccines, which independently achieve 48% and 68% reductions in malaria cases, can achieve 91% reduction when combined.
Targeting Epigenetic Proteins to Prevent Breast CancerNews
Researchers have discovered that epigenetic proteins promote the proliferation of mammary gland stem cells in response to the sex hormone progesterone. The study suggests that inhibiting these proteins with drugs could prevent the development of breast cancer in women at high risk of the disease.READ MORE
Targeting the Engine Room of the Cancer CellNews
Researchers at Columbia University Irving Medical Center (CUIMC) have developed a highly innovative computational framework that can support personalized cancer treatment by matching individual tumors with the drugs or drug combinations that are most likely to kill them.READ MORE